Plain-English translation of NCT04354064 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying a new blood test called circulating tumor DNA (ctDNA) that may detect cancer recurrence earlier than current methods. This test looks for tiny traces of cancer DNA circulating in the bloodstream. The goal is to find cancer recurrence at its earliest stage, when more treatment options are still available.
Early detection of cancer recurrence gives patients more treatment choices and can lead to better outcomes. This medication could transform how doctors monitor cancer patients after treatment and help guide personalized treatment decisions.
You likely qualify if…
You likely don't qualify if…
If you are a healthy volunteer, you would donate blood and/or urine samples up to 24 times over the study period, roughly every two months. If you have been diagnosed with cancer, researchers may use tissue, blood, or urine samples that have already been collected and stored from your previous care. The study is collecting samples from people with many different types of cancer to build a reference database that will help improve how this new blood test works.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Collaborators
Roche Sequencing Solutions, The Foundation for Barnes-Jewish Hospital
Enrollment target
~100 participants
Started
May 2019
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Melissa Reimers, M.D.
Washington University School of Medicine
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.